Brokerages expect Esperion Therapeutics Inc (NASDAQ:ESPR) to announce ($1.80) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Esperion Therapeutics’ earnings. The highest EPS estimate is ($1.47) and the lowest is ($2.05). Esperion Therapeutics posted earnings per share of ($1.29) in the same quarter last year, which would suggest a negative year-over-year growth rate of 39.5%. The company is expected to announce its next earnings results on Wednesday, February 28th.
According to Zacks, analysts expect that Esperion Therapeutics will report full-year earnings of ($7.30) per share for the current year, with EPS estimates ranging from ($7.63) to ($6.90). For the next year, analysts expect that the company will post earnings of ($6.39) per share, with EPS estimates ranging from ($8.54) to ($4.65). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Esperion Therapeutics.
Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) EPS for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.07). During the same quarter last year, the business earned ($0.77) earnings per share.
Esperion Therapeutics (NASDAQ ESPR) traded up $2.83 on Friday, hitting $80.76. The company had a trading volume of 687,251 shares, compared to its average volume of 558,233. The firm has a market capitalization of $2,070.00, a price-to-earnings ratio of -11.77 and a beta of 2.73. Esperion Therapeutics has a fifty-two week low of $10.71 and a fifty-two week high of $82.18.
In other Esperion Therapeutics news, Director Nicole Vitullo sold 9,326 shares of the firm’s stock in a transaction dated Wednesday, December 6th. The stock was sold at an average price of $53.85, for a total value of $502,205.10. Following the sale, the director now directly owns 2,472 shares of the company’s stock, valued at approximately $133,117.20. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 32.50% of the stock is currently owned by company insiders.
Several institutional investors have recently added to or reduced their stakes in ESPR. Schwab Charles Investment Management Inc. raised its holdings in shares of Esperion Therapeutics by 23.8% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 68,275 shares of the biopharmaceutical company’s stock worth $3,160,000 after purchasing an additional 13,146 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Esperion Therapeutics by 9.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 114,853 shares of the biopharmaceutical company’s stock worth $5,315,000 after purchasing an additional 10,250 shares during the period. Swiss National Bank raised its holdings in shares of Esperion Therapeutics by 18.5% in the 2nd quarter. Swiss National Bank now owns 26,300 shares of the biopharmaceutical company’s stock worth $1,217,000 after purchasing an additional 4,100 shares during the period. Alliancebernstein L.P. raised its holdings in shares of Esperion Therapeutics by 5.3% in the 2nd quarter. Alliancebernstein L.P. now owns 30,070 shares of the biopharmaceutical company’s stock worth $1,392,000 after purchasing an additional 1,500 shares during the period. Finally, Teachers Advisors LLC raised its holdings in shares of Esperion Therapeutics by 382.0% in the 2nd quarter. Teachers Advisors LLC now owns 142,483 shares of the biopharmaceutical company’s stock worth $6,594,000 after purchasing an additional 112,920 shares during the period. Institutional investors own 92.30% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.com-unik.info/2018/01/23/analysts-anticipate-esperion-therapeutics-inc-espr-will-announce-earnings-of-1-80-per-share.html.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.